What's happening
Roche announced on April 16, 2026, a new global Phase 3 trial for Elevidys, the gene therapy for Duchenne muscular dystrophy developed by Sarepta Therapeutics. The placebo-controlled trial will involve approximately 100 early ambulatory boys with Duchenne muscular dystrophy over 72 weeks, with the primary endpoint measuring change in time to rise from floor velocity. All placebo patients will be eligible for crossover after the 72-week period.
Elevidys is currently approved in 9 countries, with Roche holding commercialization rights outside the United States while Sarepta markets the therapy domestically. Roche has treated more than 1,000 ambulatory boys worldwide with the gene therapy. The previous EMBARK Phase 3 trial showed a 0.64 seconds improvement in time to rise versus placebo and 6.05 seconds versus external control over three years.
Why it matters for markets
The new Phase 3 trial represents a significant opportunity for Sarepta to expand Elevidys revenue through European market access, building on the therapy's $898.7 million in net product revenue for full year 2025. Sarepta's Q4 2025 Elevidys revenue reached $110.4 million, contributing to total net product revenues of $1.864.3 billion. However, Wall Street analysts expect Elevidys 2026 sales below $500 million, falling short of Sarepta's internal projections.
The market reaction was negative, with Sarepta shares declining 3.15% to $21.05 on the announcement day and trading at $21.17 as of April 17, 2026. With a market cap of $2.22 billion, Sarepta's valuation reflects investor caution about the gene therapy's commercial trajectory. The previous EMBARK trial showed mixed results, with a 0.65-point difference versus placebo in North Star Ambulatory Assessment that was not statistically significant, though it demonstrated a 4.39-point improvement versus external control.
Sectors and assets to watch
Gene therapy companies developing treatments for rare diseases face heightened scrutiny as regulatory pathways for European approval remain challenging. Sarepta Therapeutics, with 835 employees and $2.20 billion in revenue, represents a key player in the Duchenne muscular dystrophy treatment space alongside its RNA-targeted exon-skipping therapies including Exondys 51, Vyondys 53, and Amondys 45.
Roche, with its $321.59 billion market cap and $63.36 billion in revenue, continues expanding its rare disease portfolio beyond its established oncology blockbusters like Avastin and Herceptin. The Swiss pharmaceutical giant's commitment to Elevidys reflects broader industry investment in precision genetic medicines for neuromuscular diseases.
What to watch next
Monitor the trial's enrollment timeline and interim safety data readouts over the 72-week study period, as well as regulatory feedback from European authorities on the trial design. Sarepta's quarterly Elevidys revenue reports will indicate whether the therapy can meet analyst expectations below $500 million for 2026, while Roche's patient treatment numbers outside the United States will signal international adoption rates.